A Cost Per Responder Analysis of Secukinumab Vs. Adalimumab Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatment of Ankylosing Spondylitis at 52 Weeks from the Irish Payer Perspective
Abstract
Authors
P Gunda E Nikoglou SM Jugl A Murphy